FDA ReviewedUpdated May 20, 2026

Foundayo Guide

Foundayo (orforglipron) is the first FDA-approved once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management. Approved by the FDA on April 1, 2026, Foundayo is taken as a single tablet once a day with no food or water restrictions, marking a major change from injectable GLP-1s and from oral semaglutide (Rybelsus), which has strict food and water rules. In the 72-week ATTAIN-1 phase 3 trial, the highest dose produced 12.4% mean weight loss versus 0.9% on placebo.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

At a Glance

Generic NameOrforglipron
Brand NamesFoundayo
FDA StatusFDA-approved for chronic weight management in adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and increased physical activity (April 1, 2026). Not approved for pediatric use. Cannot be used with other GLP-1 receptor agonists.[1]
Approval DateApril 1, 2026[1]

How Foundayo Works

Orforglipron is a non-peptide small molecule that binds and activates the GLP-1 receptor directly. Unlike injectable GLP-1 peptides (semaglutide, tirzepatide) or oral peptide formulations (Rybelsus), orforglipron is a true small organic molecule that survives stomach acid and digestion, eliminating the need for injection or special food restrictions. It produces the same downstream effects as injectable GLP-1 agonists: appetite suppression, slowed gastric emptying, and reduced food reward signaling.[2]

Dosing Schedule

Foundayo uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Starting dose0.8 mg orally once daily
TitrationStepwise increase: 2.5 mg, 5.5 mg, 9 mg
Higher doses14.5 mg, 17.2 mg (maintenance, highest tested in ATTAIN-1)

Side Effects

Common: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, swollen belly, fatigue, belching, heartburn, gas, hair loss. Serious: pancreatitis, dehydration leading to kidney problems, gallbladder disease, hypoglycemia (especially with insulin/sulfonylureas), serious allergic reactions, diabetic retinopathy progression in T2D patients, increased aspiration risk during anesthesia. Boxed warning: thyroid C-cell tumors observed in animal studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[1][2]

This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].

Clinical Trial Results

ATTAIN-1 (NCT05869903) was a 72-week phase 3 randomized placebo-controlled trial of 3,127 adults with obesity or overweight plus a weight-related comorbidity (no diabetes), conducted across 10 countries. Highest dose produced 12.4% mean body weight reduction (~27 lbs) versus 0.9% on placebo (efficacy estimand). Treatment-regimen estimand: 11.1% (~25 lbs) vs 2.1% placebo. Foundayo also reduced waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across all doses. ATTAIN-2 in patients with type 2 diabetes is ongoing.[2]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Foundayo

These telehealth providers offer access to orforglipron or compounded equivalents with online consultations and home delivery.

8.7/ 10

Amazon One Medical

Best for: the most authoritative branded GLP-1 channel with same-day delivery and integrated manufacturer savings

★★★★☆4.4

Editorial score · methodology

$25/mo
BrandOrforglipron
Get StartedRead full Amazon One Medical review →
8.5/ 10

LillyDirect Foundayo

Best for: patients with commercial insurance who want the cheapest legal brand-name GLP-1

★★★★☆4.3

Editorial score · methodology

$25/mo
BrandOrforglipron
Get StartedRead full LillyDirect Foundayo review →
8.4/ 10

GoodRx

Best for: self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies

★★★★☆4.2

Editorial score · methodology

$149/mo
BrandOrforglipronTirzepatide
Get StartedRead full GoodRx review →
7.9/ 10

Ro

Best for: broadest GLP-1 formulary including Foundayo on day-one of launch

★★★★☆4

Editorial score · methodology

$149/mo
BrandOrforglipron
Get StartedRead full Ro review →

Cost Comparison

Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded orforglipron from licensed 503A and 503B pharmacies is legal under federal compounding law[3], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List[4]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[5]. Prices may vary based on dose and promo availability.

ProviderStarting Price
Amazon One Medical$25/moVisit
LillyDirect Foundayo$25/moVisit
GoodRx$149/moVisit
Ro$149/moVisit

Related Research on Foundayo

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

Diabetes Weight Loss Drug — Which Is Which? Untangling Ozempic, Mounjaro, Wegovy, Zepbound, Foundayo (2026)
Confused by all the GLP-1 brand names? Ozempic and Mounjaro are FDA-approved for type 2 diabetes. Wegovy, Zepbound, Foundayo, and Saxenda are FDA-approved for chronic weight management. Some share active ingredients with different brand names. This is the short, plain-English untangling — which drug is for diabetes, which is for weight loss, and what insurance will and will not cover.
7 min read7 citations
What Is the Best GLP-1 for Weight Loss? Ranked by FDA Evidence (2026)
There is no single "best" GLP-1 — there are four FDA-approved AOMs ranked by different criteria. Ranked by raw % total body-weight loss: Zepbound (tirzepatide 15 mg) -20.9% at 72 wk in SURMOUNT-1 (Jastreboff NEJM 2022) > Wegovy (semaglutide 2.4 mg) -14.9% at 68 wk in STEP-1 (Wilding NEJM 2021) > Foundayo (orforglipron 17.2 mg oral) -11.1% at 72 wk in ATTAIN-1 (Wharton NEJM 2025) > Saxenda (liraglutide 3 mg) -8.0% at 56 wk in SCALE (Pi-Sunyer NEJM 2015). The head-to-head SURMOUNT-5 trial (Aronne NEJM 2025) confirmed tirzepatide produces greater weight loss than semaglutide directly. By cardiovascular evidence: Wegovy wins — the SELECT trial (Lincoff NEJM 2023) is the only GLP-1 obesity trial with a positive MACE outcome (HR 0.80). By oral route: Foundayo is the only FDA-approved oral GLP-1 for chronic weight management. By cost (cash-pay 2026): Foundayo $149/mo ties as cheapest. By needle aversion: Foundayo. By weight-loss magnitude: Zepbound. By CV protection: Wegovy. Pipeline retatrutide hit -24.2% in phase 2 (Jastreboff NEJM 2023) but is investigational. The honest answer depends on which criterion matters for YOUR goal.
13 min read7 citations
Does Pilates Cause Weight Loss? Honest Evidence Review
Pilates does not produce clinically meaningful weight loss directly. Modest calorie burn and improvements in core strength + flexibility. Best paired with caloric deficit + resistance training.
17 min read12 citations
Oregon Medicaid GLP-1 Coverage 2026: PA Pathway, Eligibility & Appeals
Oregon Health Plan (OHP, ~1.4M enrollees, OHA) DOES NOT cover GLP-1s for adult chronic weight management. The exclusion is anchored at HERC Prioritized List Guideline Note 5 at Line 317 — verbatim: 'Pharmacological treatments and devices ... for obesity are not intended to be.
27 min read17 citations
What Are Peptides for Weight Loss? Definition, Compounded Peptide Landscape + Evidence Review
Peptides for weight loss fall into three distinct categories: (1) FDA-approved peptide drugs — Wegovy (semaglutide 31aa, -14.9% STEP-1 PMID 33567185), Zepbound (tirzepatide 39aa, -20.9% SURMOUNT-1 PMID 35658024), Saxenda (liraglutide 34aa, -8.0% SCALE PMID 26132939); (2) compounded peptide versions of those drugs from 503A pharmacies — not FDA-approved products, regulatory landscape changed post-Feb 2025; (3) research peptides (BPC-157, AOD-9604, MOTS-c, GHK-Cu, sermorelin) — NONE FDA-approved for weight loss, no Phase 3 human weight-loss RCT in PubMed. Tesamorelin (Egrifta SV) is FDA-approved but ONLY for HIV-associated lipodystrophy (DailyMed SetID 3d783378 verbatim: 'reduction of excess abdominal fat in HIV-infected patients with lipodystrophy') — not for general weight loss. Foundayo (orforglipron) is FDA-approved for weight management (April 2026) but is NOT a peptide — it is a non-peptide small-molecule GLP-1 RA. Verified 2026-05-10.
16 min read13 citations
UnitedHealthcare GLP-1 Prior Authorization Guide: Wegovy, Zepbound, and Saxenda PA Criteria (2026)
UHC's primary-source PA criteria for GLP-1 weight-loss drugs — CDG CS10028.1 (reviewed 09/04/2024), OptumRx January 2025 Wegovy-preferred formulary update, CDG CS10191 for Foundayo (05/01/2026), New York and Massachusetts state mandate overrides, and the UHC Medicare Advantage GLP-1 Bridge. Covers OptumRx PBM structure, step-therapy, self-funded vs fully-insured dynamics, and the full appeal process. Every primary source verified 2026-05-10.
16 min read9 citations

Frequently Asked Questions

Sources & methodology — as of May 2026
  1. 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  3. 3.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  4. 4.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  5. 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Glossary references

Key terms in this article, linked to their canonical definitions.